The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Glucose Tolerance and Cardiovascular Mortality: Comparison of Fasting and 2-Hour Diagnostic Criteria
(2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.3.397 · Cited by 1,371
Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
Mentlein, R. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00089-0 · Cited by 1,272
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Self-citationKieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Khaw, K.-T. (2001) · BMJ · doi:10.1136/bmj.322.7277.15 · Cited by 1,017
Diabetes Control and Complications Trial (DCCT) Research Group (1996) · Diabetes · doi:10.2337/diab.45.10.1289 · Cited by 597
Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26
Marguet, D., Baggio, L., Kobayashi, T., Bernard, A.-M., Pierres, M., Nielsen, P. F., Ribel, U., Watanabe, T., Drucker, D. J., & Wagtmann, N. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120069197 · Cited by 538
Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes
Lankas, G. R., Leiting, B., Roy, R. S., Eiermann, G. J., Beconi, M. G., Biftu, T., Chan, C.-C., Edmondson, S., Feeney, W. P., He, H., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.10.2988 · Cited by 491
Self-citationInhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
CD26, let it cut or cut it down
De Meester, I., Korom, S., Van Damme, J., & Scharpé, S. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01486-3 · Cited by 451
Mu, J., Woods, J., Zhou, Y.-P., Roy, R. S., Li, Z., Zycband, E., Feng, Y., Zhu, L., Li, C., Howard, A. D., et al. (2006) · Diabetes · doi:10.2337/db05-1602 · Cited by 449
Self-citationVilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444
Ahrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.869 · Cited by 421
Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance
Conarello, S. L., Li, Z., Ronan, J., Roy, R. S., Zhu, L., Jiang, G., Liu, F., Woods, J., Zycband, E., Moller, D. E., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0631828100 · Cited by 347
Self-citationPospisilik, J. A., Martin, J., Doty, T., Ehses, J. A., Pamir, N., Lynn, F. C., Piteau, S., Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.741 · Cited by 332
Hansotia, T., Baggio, L. L., Delmeire, D., Hinke, S. A., Yamada, Y., Tsukiyama, K., Seino, Y., Holst, J. J., Schuit, F., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1326 · Cited by 309
Abbott, C. A., Yu, D. M. T., Woollatt, E., Sutherland, G. R., McCaughan, G. W., & Gorrell, M. D. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01617.x · Cited by 271
Knudsen, L. B., & Pridal, L. (1996) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00795-9 · Cited by 248
Balkan, B., Kwasnik, L., Miserendino, R., Holst, J. J., & Li, X. (1999) · Diabetologia · doi:10.1007/s001250051445 · Cited by 209
Reimer, M., Holst, J., & Ahren, B. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1460717 · Cited by 195
Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes
Mest, H. ‐., & Mentlein, R. (2005) · Diabetologia · doi:10.1007/s00125-005-1707-5 · Cited by 148
Hüttner, S., Graefe-Mody, E. U., Withopf, B., Ring, A., & Dugi, K. A. (2008) · The Journal of Clinical Pharmacology · doi:10.1177/0091270008323753 · Cited by 139
Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
Williams‐Herman, D., Round, E., Swern, A. S., Musser, B. J., Davies, M. J., Stein, P. P., Kaufman, K. D., & Amatruda, J. M. (2008) · BMC Endocrine Disorders · doi:10.1186/1472-6823-8-14 · Cited by 132
Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities?
Šedo, A., & Malík, R. (2001) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(01)00278-3 · Cited by 132
Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes
Åhrén, B. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802584126 · Cited by 102
Gault, V. A., Parker, J. C., Harriott, P., Flatt, P. R., & O'Harte, F. P. M. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1750525 · Cited by 102
Natural Substrates of Dipeptidyl Peptidase IV
Meester, I. D., Durinx, C., Bal, G., Proost, P., Struyf, S., Goossens, F., Augustyns, K., & Scharpé, S. (2002) · Advances in experimental medicine and biology · doi:10.1007/0-306-46826-3_7 · Cited by 86
Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update)
Gallwitz, B. (2007) · Drugs of today · doi:10.1358/dot.2007.43.11.1157620 · Cited by 71
Self-citationThe islet enhancer vildagliptin: mechanisms of improved glucose metabolism
Åhrén, B., & Foley, J. E. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01685.x · Cited by 67
Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes
Gallwitz, B. (2007) · Drugs of today · doi:10.1358/dot.2007.43.1.1043909 · Cited by 55
Self-citationSaxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Gallwitz, B. (2008) · PubMed · Cited by 39
Self-citationDeacon, C. F. (2008) · PubMed · Cited by 37
Ristic, S., & BATES, P. C. (2006) · Drugs of today · doi:10.1358/dot.2006.42.8.996570 · Cited by 26
Cited by
Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention
Wu, Y., Ding, Y., Tanaka, Y., & Zhang, W. (2014) · International Journal of Medical Sciences · doi:10.7150/ijms.10001 · Cited by 1,279
GLP-1 receptor agonists and kidney protection
Greco, E., Russo, G., Giandalia, A., Viazzi, F., Pontremoli, R., & De Cosmo, S. (2019) · Medicina · doi:10.3390/medicina55060233 · Cited by 173
Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment
Neumiller, J. J. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.024 · Cited by 47
Rabizadeh, S., Tavakoli Ardakani, M. A., Mouodi, M., Bitaraf, M., Shab-Bidar, S., Esteghamati, A., & Nakhjavani, M. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01434-7 · Cited by 8
Ansari, P., Khan, J. T., Choudhary, S., Reberio, A. D., Kumar, S., Seidel, V., Abdel-Wahab, Y. H. A., & Flatt, P. R. (2024) · doi:10.20944/preprints202408.1739.v1 · Cited by 89
Metadata
- Authors
- Thornberry, N. A., & Gallwitz, B.
- Venue
- Best Practice & Research Clinical Endocrinology & Metabolism
- Publisher
- Elsevier BV
- Published
- 2009-08
- Volume
- 23
- Issue
- 4
- Pages
- 479-486
- ISSN
- 1521-690X (ISSN-L)
- OpenAlex
- W2002881577
- Cited by
- 268
- References
- 40
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.